...
首页> 外文期刊>Clinical & translational oncology : >Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls
【24h】

Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls

机译:CD34 +造血细胞中PI3K / AKT,WNT / B-Catenin,SHH,NOTCH和MAPK信号通路中基因的表达差异,从慢性骨髓白血病和健康对照中获得慢性相位患者

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Purpose The fusion gene BCR-ABL has an important role to the progression of chronic myeloid leukemia (CML) and several signaling pathways have been characterized as responsible for the terminal blastic phase (BP). However, the initial phase, the chronic phase (CP), is long lasting and there is much yet to be understood about the critical role of BCR-ABL in this phase. This study aims to evaluate transcriptional deregulation in CD34+ hematopoietic cells (CD34+ cells) from patients with untreated newly diagnosed CML compared with CD34+HC from healthy controls. Methods Gene expression profiling in CML-CD34 cells and CD34 cells from healthy controls were used for this purpose with emphasis on five main pathways important for enhanced proliferation/survival, enhanced self-renewal and block of myeloid differentiation. Results We found 835 genes with changed expression levels (fold change ≥?±2) in CML-CD34 cells compared with CD34 cells. These include genes belonging to PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways. Four of these pathways converge to MYC activation. We also identified five transcripts upregulated in CD34-CML patients named OSBPL9, MEK2, p90RSK, TCF4 and FZD7 that can be potential biomarkers in CD34-CML-CP. Conclusion We show several mRNAs up- or downregulated in CD34-CML during the chronic phase.
机译:摘要目的融合基因BCR-ABL对慢性髓性白血病(CML)的进展具有重要作用,并且已经表征了几种信号通路对末端弹性相(BP)负责。然而,初始阶段,慢性阶段(CP)是持久的,并且关于BCR-ABL在该阶段的关键作用尚待理解。本研究旨在评估与来自健康对照的CD34 + HC的未经处理的新诊断的CML患者评估CD34 +造血细胞(CD34 +细胞)的转录病程。方法使用来自健康对照的CML-CD34细胞和CD34细胞中的基因表达分析用于此目的,重点是增强增殖/存活,增强的自我更新和骨髓分化障碍的五个主要途径。结果,与CMML-CD34细胞中,我们发现835个基因在CML-CD34细胞中改变了表达水平(折叠变化≥≤2)。这些包括属于pi3k / akt,wnt / b-catenin,shh,缺口和mapk信号传导途径的基因。这些途径中的四个会聚到Myc激活。我们还确定了在CD34-CML患者中上调的五个转录物,名为OSBPL9,MEK2,P90RSK,TCF4和FZD7,可以是CD34-CML-CP中的潜在生物标志物。结论在慢性阶段,我们在CD34-CML中显示出几种mRNA或下调。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号